Lactosylceramide (LacCer)

Lactosylceramide is a diglycosylated glycosphingolipid composed of a ceramide backbone covalently linked to a lactose moiety (specifically, β-D-galactosyl-(1→4)-β-D-glucosylceramide)[1][2][3]. It is found in small amounts in most animal tissues, enriched in the microdomains (lipid rafts) of plasma membranes, where it serves structural, signaling, and pattern-recognition functions[1][2][5][6][7]. Biosynthetically, lactosylceramide is a crucial intermediate, being the precursor to most complex glycosphingolipids including gangliosides and sulfatides, and is synthesized by β-1,4-galactosyltransferases in the Golgi apparatus[1][5][6]. It mediates cell proliferation, adhesion, migration, angiogenesis, apoptosis, and immune recognition, and is implicated in cardiovascular disease, cancer, Fabry disease, inflammation, neurodegeneration, and host-pathogen interactions[2][5][6][7]. Accumulation or dysregulation of lactosylceramide is pathogenic in several disorders, making its metabolic pathways a therapeutic target for small-molecule inhibitors and other interventions[2][5][6][7].

Other names

Cytolipin HCDw17 antigenCD17ceramide lactosideceramide dihexosideCDHN-lignoceroyl-1-sphingosyl lactosidebeta-D-galactosyl-(1-4)-D-glucosylceramidebeta-D-galactosyl-1,4-beta-D-glucosylceramideglycosyl-N-acylsphingosine

Inhibition of synthesis (by targeting LacCer synthase, beta-1,4-galactosyltransferase); Modulation of downstream signaling pathways (e.g., inhibition of oxygen-sensitive signaling, modulation of immune cell responses)